#JPM2026 Day One
The conference kicked off in San Francisco with bold strategies, major biopharma pipeline updates, and transformative visions from leading pharmaceutical companies, biotech innovators, and healthcare investors. Our Day 1 coverage brings you the most important takeaways, so you stay ahead of the curve.
What’s Inside
- J&J bets $55B on U.S. growth: Major investment in manufacturing and R&D, plus Ottava robotic surgery system and neuroscience push.
- Novartis eyes $80B revenue: Pipeline packed with Rhapsido, ianalumab, and 14 submission-ready assets in next two years.
- Alnylam’s bold 2030 vision: Targeting global TTR leadership, 25%+ CAGR, and 40+ clinical programs powered by RNAi innovation.
- CRISPR drives gene-editing frontier: CASGEVY global rollout and promising in vivo programs for cardiovascular and autoimmune diseases.
Explore the full report for detailed company insights, pipeline catalysts, and strategic outlooks.
